S. Alonso-Gil

发表

The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury

V. Palomo, Ana Martínez, C. Gil, 2012, Journal of neurochemistry.

Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders.

Ana Martínez, V. Palomo, C. Gil, 2014, ACS chemical neuroscience.

Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.

C. Pérez, J. Souza, D. Perez, 2012, European journal of medicinal chemistry.

Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1,2,3,4-tetrahydro-β-carboline (Pinoline) and Melatonin-Pinoline Hybrids.

C. Pérez, M. de la Fuente Revenga, M. Yáñez, 2015, ACS chemical neuroscience.

Neuroprotective and Anti-Inflammatory Effects of Linoleic Acid in Models of Parkinson’s Disease: The Implication of Lipid Droplets and Lipophagy

M. Niso-Santano, J. M. Fuentes, M. Cortés-Canteli, 2022, Cells.

Ambra1 haploinsufficiency in CD1 mice results in metabolic alterations and exacerbates age-associated retinal degeneration

P. Boya, G. Mariño, J. M. Fuentes, 2022, Autophagy.

5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.

C. Pérez, Ana Martínez, N. Campillo, 2012, Journal of medicinal chemistry.

N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo

J. Riba, J. A. López-Moreno, J. Calleja-Conde, 2020, Translational Psychiatry.

The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro

A. Feilding, J. Riba, M. de la Fuente Revenga, 2017, Scientific Reports.

Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.

M. de la Fuente Revenga, M. Rodríguez-Franco, D. Caignard, 2015, Journal of medicinal chemistry.

C/EBPβ Regulates TFAM Expression, Mitochondrial Function and Autophagy in Cellular Models of Parkinson’s Disease

E. Carro, M. Cortés-Canteli, E. Giné, 2023, International journal of molecular sciences.

Ambra1 haploinsufficiency results in metabolic alterations and exacerbates age-associated retinal degeneration

P. Boya, G. Mariño, J. M. Fuentes, 2022, bioRxiv.

Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson’s Disease

A. Pérez-Castillo, Ángel Santos, S. Alonso-Gil, 2019, Molecular Neurobiology.

Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo

Ana Martínez, V. Echeverry-Alzate, J. A. López-Moreno, 2017, Stem cells.

Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.

Ana Martínez, V. Palomo, C. Gil, 2012, ACS chemical neuroscience.

Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice

Ana Martínez, C. Gil, A. Pérez-Castillo, 2015, Neurobiology of Aging.

The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro

A. Feilding, J. Riba, M. de la Fuente Revenga, 2017, Scientific Reports.

Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease

C. Pérez, Ana Martínez, C. Gil, 2011, PloS one.

Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

C. Pérez, V. Palomo, D. Perez, 2013, ACS chemical neuroscience.

CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson’s disease

E. Giné, A. Pérez-Castillo, Ángel Santos, 2017, Scientific Reports.

PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis

L. Mestre, C. Guaza, C. Gil, 2015, British journal of pharmacology.

CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson’s disease

A. Pérez-Castillo, Ángel Santos, Elena Hernández-Encinas, 2017, Scientific Reports.

Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian Rats

Ana Martínez, C. Gil, A. Pérez-Castillo, 2015, Stem cells translational medicine.

New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.

C. Pérez, Manuela G. López, M. Villarroya, 2014, Journal of medicinal chemistry.

Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.

M. Loza, J. Brea, M. Cadavid, 2014, Journal of medicinal chemistry.

Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.

Cristina Val, M. Loza, J. Brea, 2012, Journal of medicinal chemistry.

Phosphodiesterase 7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. Running title: PDE7 inhibitors for PPMS

L. Mestre, C. Guaza, C. Gil, 2015 .

Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson’s Disease

A. Pérez-Castillo, Ángel Santos, S. Alonso-Gil, 2019, Molecular Neurobiology.

Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

V. Palomo, D. Perez, C. Gil, 2013, ACS chemical neuroscience.

Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.

M. Loza, J. Brea, M. Cadavid, 2014, Journal of medicinal chemistry.